Target Price | $41.78 |
Price | $6.89 |
Potential |
506.42%
register free of charge
|
Number of Estimates | 23 |
23 Analysts have issued a price target Intellia Therapeutics, Inc. 2026 .
The average Intellia Therapeutics, Inc. target price is $41.78.
This is
506.42%
register free of charge
$106.00
1,438.46%
register free of charge
$9.00
30.62%
register free of charge
|
|
A rating was issued by 28 analysts: 20 Analysts recommend Intellia Therapeutics, Inc. to buy, 7 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Intellia Therapeutics, Inc. stock has an average upside potential 2026 of
506.42%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 57.88 | 49.44 |
59.54% | 14.58% | |
EBITDA Margin | -905.29% | -1,007.71% |
35.13% | 11.31% | |
Net Margin | -925.46% | -963.86% |
39.28% | 4.15% |
24 Analysts have issued a sales forecast Intellia Therapeutics, Inc. 2025 . The average Intellia Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Intellia Therapeutics, Inc. EBITDA forecast 2025. The average Intellia Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Intellia Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Intellia Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -5.25 | -4.67 |
3.14% | 11.05% | |
P/E | negative | |
EV/Sales | 6.51 |
25 Analysts have issued a Intellia Therapeutics, Inc. forecast for earnings per share. The average Intellia Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Intellia Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 05 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Feb 28 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.